Sareum Holdings [LON:SAR] is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of autoimmune diseases and cancer. Sareum Holdings aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.
LSE:SAR quotes by TradingView
Since COVID19, the company has been looking at how its small molecule inhibitors could be used in severe cases of the coronavirus
24th March 2021
27th October 2020